Indivior Pharmaceuticals annual r&d spending
2021
2022
2023
2024
2025
Indivior Pharmaceuticals R&D Spending Growth & History (INDV)
Indivior Pharmaceuticals's r&d spending was $97.0M for fiscal 2025.
View full Indivior Pharmaceuticals company overviewIndivior Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $97.0M | −$10.0M | −9.35% |
| 2024 | 2024-12-31 | $107.0M | −$9.0M | −7.76% |
| 2023 | 2023-12-31 | $116.0M | $42.0M | +56.76% |
| 2022 | 2022-12-31 | $74.0M | $22.0M | +42.31% |
| 2021 | 2021-12-31 | $52.0M | — | — |
Indivior Pharmaceuticals quarterly r&d spending
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.0M | −$9.0M | −42.86% |
| Q1 2026 | 2026-03-31 | $16.0M | −$6.0M | −27.27% |
| Q4 2025 | 2025-12-31 | $21.0M | −$10.0M | −32.26% |
| Q3 2025 | 2025-09-30 | $33.0M | $11.0M | +50.00% |
| Q2 2025 | 2025-06-30 | $21.0M | −$5.0M | −19.23% |
| Q1 2025 | 2025-03-31 | $22.0M | −$6.0M | −21.43% |
| Q4 2024 | 2024-12-31 | $31.0M | — | — |
| Q3 2024 | 2024-09-30 | $22.0M | — | — |
| Q2 2024 | 2024-06-30 | $26.0M | — | — |
| Q1 2024 | 2024-03-31 | $28.0M | — | — |
Indivior Pharmaceuticals r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Indivior Pharmaceuticals's r&d spending increased from $52.0M to $97.0M, a change of $45.0M. The latest reported quarter, Q2 2026, shows $12.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Indivior Pharmaceuticals source filings ↗